Quick-Med Tech announces advances in patent coverage for NIMBUS ® technology
Life Sciences Company Quick-Med Technologies Inc has announced advances in patent coverage in China, Australia, and Mexico for its novel, non-leaching NIMBUS ® antimicrobial technology.
The Australian Patent Office and the patent office of Mexico, Instituto Mexicano de la Propiedad Industrial have given the company pending patent entitled Disinfectant with Quaternary Ammonium Polymer and Copolymers in their respective jurisdictions, the news reports said.
The State Intellectual Property of the People’s Republic of China has also issued a notification to grant an invention patent for this pending patent in China.
The patents will expand the international intellectual property coverage for NIMBUS, the news reports said. NIMBUS technology includes the chemistry of antimicrobials that comprise a high charge density polycation built into the backbone of various polymers.
The new patents are the key composition of matter patents that cover the incorporation of a NIMBUS polycation into the main chain of a urethane polymer. The patents also provides protection for various claims regarding the efficacy and durability of an antimicrobial polyurethane.
Dr. William Toreki, co-inventor and Quick-Med’s Vice President of Research & Development said, “This patent adds an exciting new dimension to our NIMBUS technology.”
Quick-Med Technologies is a life sciences company engaged in developing proprietary, broad-based technologies to prevent infection and control the consumer and healthcare markets. The company commercialized its NIMBUS technology in traditional wound care products in 2009 and is also developing NIMBUS applications in other medical device areas including adhesives, foams, hydrogels, films, hydrocolloids, and catheters.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”